130 related articles for article (PubMed ID: 18691133)
1. D2 receptor partial agonists: treatment of CNS disorders of dopamine function.
Kehne JH; Andree TH; Heinrich JN
Curr Top Med Chem; 2008; 8(12):1068-88. PubMed ID: 18691133
[TBL] [Abstract][Full Text] [Related]
2. Receptor-binding and pharmacokinetic properties of dopaminergic agonists.
Kvernmo T; Houben J; Sylte I
Curr Top Med Chem; 2008; 8(12):1049-67. PubMed ID: 18691132
[TBL] [Abstract][Full Text] [Related]
3. Chronic activation of the D2 autoreceptor inhibits both glutamate and dopamine synapse formation and alters the intrinsic properties of mesencephalic dopamine neurons in vitro.
Fasano C; Kortleven C; Trudeau LE
Eur J Neurosci; 2010 Nov; 32(9):1433-41. PubMed ID: 20846243
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity.
Sammut S; Bray KE; West AR
Psychopharmacology (Berl); 2007 Apr; 191(3):793-803. PubMed ID: 17206493
[TBL] [Abstract][Full Text] [Related]
5. Dopamine acting at D1-like, D2-like and α1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex.
Özkan M; Johnson NW; Sehirli US; Woodhall GL; Stanford IM
PLoS One; 2017; 12(7):e0181633. PubMed ID: 28732063
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists.
Boulay D; Depoortere R; Perrault G; Borrelli E; Sanger DJ
Neuropharmacology; 1999 Sep; 38(9):1389-96. PubMed ID: 10471093
[TBL] [Abstract][Full Text] [Related]
7. Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice.
Gomez-Sintes R; Bortolozzi A; Artigas F; Lucas JJ
Eur Neuropsychopharmacol; 2014 Sep; 24(9):1524-33. PubMed ID: 25088904
[TBL] [Abstract][Full Text] [Related]
8. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
[TBL] [Abstract][Full Text] [Related]
9. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
10. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.
Inoue A; Nakata Y
Jpn J Pharmacol; 2001 Aug; 86(4):376-80. PubMed ID: 11569610
[TBL] [Abstract][Full Text] [Related]
11. Lack of D2 receptor mediated regulation of dopamine synthesis in A11 diencephalospinal neurons in male and female mice.
Pappas SS; Behrouz B; Janis KL; Goudreau JL; Lookingland KJ
Brain Res; 2008 Jun; 1214():1-10. PubMed ID: 18462709
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of action of novel antipsychotic drugs.
Meltzer HY
Schizophr Bull; 1991; 17(2):263-87. PubMed ID: 1679253
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
14. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
[TBL] [Abstract][Full Text] [Related]
15. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
Costentin J
Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
van Vliet LA; Rodenhuis N; Dijkstra D; Wikström H; Pugsley TA; Serpa KA; Meltzer LT; Heffner TG; Wise LD; Lajiness ME; Huff RM; Svensson K; Sundell S; Lundmark M
J Med Chem; 2000 Jul; 43(15):2871-82. PubMed ID: 10956195
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
Ryoo HL; Pierrotti D; Joyce JN
Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
[TBL] [Abstract][Full Text] [Related]
18. Ventral striatal dopamine modulation of different forms of behavioral flexibility.
Haluk DM; Floresco SB
Neuropsychopharmacology; 2009 Jul; 34(8):2041-52. PubMed ID: 19262467
[TBL] [Abstract][Full Text] [Related]
19. D2-like dopamine receptor activation excites rat dorsal raphe 5-HT neurons in vitro.
Haj-Dahmane S
Eur J Neurosci; 2001 Jul; 14(1):125-34. PubMed ID: 11488956
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
Wei W; Ding S; Zhou FM
J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
